These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28467612)

  • 1. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
    Quintavalle C; Burmeister K; Piscuoglio S; Quagliata L; Karamitopoulou E; Sepe R; Fusco A; Terracciano LM; Andersen JB; Pallante P; Matter MS
    Mol Carcinog; 2017 Sep; 56(9):2146-2157. PubMed ID: 28467612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of cullin 3 inhibits progressive phenotypes and increases chemosensitivity in cholangiocarcinoma cells.
    Pratummanee K; Kerdkumthong K; Roytrakul S; Tantimetta P; Runsaeng P; Saeheng S; Obchoei S
    Mol Med Rep; 2024 Nov; 30(5):. PubMed ID: 39239747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
    Lu M; Qin X; Zhou Y; Li G; Liu Z; Geng X; Yue H
    Cell Death Dis; 2021 Jan; 12(1):72. PubMed ID: 33436545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
    Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
    Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
    Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
    Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
    Choodetwattana P; Proungvitaya S; Jearanaikoon P; Limpaiboon T
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2745-2748. PubMed ID: 31554372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
    Jaidee R; Kukongviriyapan V; Senggunprai L; Prawan A; Jusakul A; Laphanuwat P; Kongpetch S
    Life Sci; 2022 May; 296():120427. PubMed ID: 35218764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
    Okamoto K; Miyoshi K; Murawaki Y
    PLoS One; 2013; 8(10):e77623. PubMed ID: 24147037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annexin A1: A new immunohistological marker of cholangiocarcinoma.
    Hongsrichan N; Rucksaken R; Chamgramol Y; Pinlaor P; Techasen A; Yongvanit P; Khuntikeo N; Pairojkul C; Pinlaor S
    World J Gastroenterol; 2013 Apr; 19(16):2456-65. PubMed ID: 23674846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc.
    Li Z; Liu J; Chen T; Sun R; Liu Z; Qiu B; Xu Y; Zhang Z
    J Exp Clin Cancer Res; 2021 Mar; 40(1):86. PubMed ID: 33648560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
    Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
    BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics and Bioinformatics Identify Drug-Resistant-Related Genes with Prognostic Potential in Cholangiocarcinoma.
    Kerdkumthong K; Roytrakul S; Songsurin K; Pratummanee K; Runsaeng P; Obchoei S
    Biomolecules; 2024 Aug; 14(8):. PubMed ID: 39199357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
    Liu B; Hu Y; Qin L; Peng XB; Huang YX
    Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N; Watanabe T; Izumisato Y; Suzuki Y; Masaki T; Mori T; Sugiyama M; Fusco A; Atomi Y
    J Gastroenterol; 2003; 38(12):1144-9. PubMed ID: 14714251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.
    Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W
    Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway.
    Thongpon P; Intuyod K; Chomwong S; Pongking T; Klungsaeng S; Muisuk K; Charoenram N; Sitthirach C; Thanan R; Pinlaor P; Pinlaor S
    Sci Rep; 2024 Jul; 14(1):16059. PubMed ID: 38992159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative proteomics analysis reveals possible anticancer mechanisms of 5'-deoxy-5'-methylthioadenosine in cholangiocarcinoma cells.
    Kerdkumthong K; Nanarong S; Roytrakul S; Pitakpornpreecha T; Tantimetta P; Runsaeng P; Obchoei S
    PLoS One; 2024; 19(6):e0306060. PubMed ID: 38923999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma.
    Weng S; Janssen HLA; Zhang N; Tang W; Bai E; Yang B; Dong L
    Dig Dis Sci; 2020 Apr; 65(4):1053-1063. PubMed ID: 31562609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.